Rifaximin CAS:80621-81-4

Rifaximin is primarily utilized in the management of gastrointestinal disorders associated with bacterial overgrowth or infection. In cases of traveler's diarrhea, rifaximin is effective against pathogens like Escherichia coli and other enteric bacteria, providing symptomatic relief and reducing the duration of diarrhea episodes in individuals traveling to regions with poor sanitation. For patients with irritable bowel syndrome with diarrhea (IBS-D), rifaximin can help alleviate symptoms by targeting bacterial imbalances in the gut microbiota, leading to improved bowel function and reduced abdominal discomfort. The localized action of rifaximin in the intestines minimizes systemic exposure and side effects commonly associated with systemic antibiotics. In hepatic encephalopathy, rifaximin is used to reduce ammonia production by gut bacteria, thereby decreasing neurotoxic effects on the brain and improving cognitive function in patients with liver disease. Its non-absorbable nature allows for targeted treatment of the gut microbiota without affecting systemic drug levels. Healthcare providers may also consider rifaximin for other gastrointestinal conditions, such as small intestinal bacterial overgrowth (SIBO) and diverticular disease, where bacterial imbalances play a role in symptom development. By modulating the gut microbiota, rifaximin offers a therapeutic approach to restore microbial balance and alleviate gastrointestinal symptoms in various clinical settings.